🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are escalating globally, with data suggesting over 82 million instances per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per findings released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The trial enrolled nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced positive views. Access to a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.